全文获取类型
收费全文 | 20908篇 |
免费 | 841篇 |
国内免费 | 86篇 |
专业分类
耳鼻咽喉 | 334篇 |
儿科学 | 582篇 |
妇产科学 | 530篇 |
基础医学 | 3752篇 |
口腔科学 | 515篇 |
临床医学 | 1322篇 |
内科学 | 2672篇 |
皮肤病学 | 669篇 |
神经病学 | 1821篇 |
特种医学 | 1902篇 |
外科学 | 2953篇 |
综合类 | 209篇 |
一般理论 | 3篇 |
预防医学 | 1548篇 |
眼科学 | 317篇 |
药学 | 1853篇 |
中国医学 | 134篇 |
肿瘤学 | 719篇 |
出版年
2023年 | 107篇 |
2022年 | 123篇 |
2021年 | 255篇 |
2020年 | 205篇 |
2019年 | 281篇 |
2018年 | 517篇 |
2017年 | 400篇 |
2016年 | 512篇 |
2015年 | 467篇 |
2014年 | 645篇 |
2013年 | 1067篇 |
2012年 | 1524篇 |
2011年 | 1809篇 |
2010年 | 1006篇 |
2009年 | 527篇 |
2008年 | 1184篇 |
2007年 | 1350篇 |
2006年 | 1300篇 |
2005年 | 1101篇 |
2004年 | 1034篇 |
2003年 | 1037篇 |
2002年 | 859篇 |
2001年 | 573篇 |
2000年 | 734篇 |
1999年 | 466篇 |
1998年 | 183篇 |
1997年 | 152篇 |
1996年 | 105篇 |
1995年 | 119篇 |
1994年 | 84篇 |
1993年 | 59篇 |
1992年 | 92篇 |
1991年 | 83篇 |
1990年 | 93篇 |
1989年 | 81篇 |
1988年 | 88篇 |
1987年 | 56篇 |
1986年 | 55篇 |
1985年 | 76篇 |
1984年 | 71篇 |
1983年 | 74篇 |
1982年 | 66篇 |
1981年 | 68篇 |
1980年 | 64篇 |
1979年 | 66篇 |
1978年 | 76篇 |
1977年 | 55篇 |
1976年 | 60篇 |
1975年 | 65篇 |
1974年 | 50篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Formulation and in Vitro-in Vivo Evaluation of Sustained-Release Lithium Carbonate Tablets 总被引:1,自引:0,他引:1
Çiftçi Kadriye Çapan Yilmaz Öztürk Orhan Hincal A. Atilla 《Pharmaceutical research》1990,7(4):359-363
The release of lithium carbonate incorporated into polymethylmethacrylate, poly vinyl chloride, hy-drogenated vegetable oil, and carbomer matrix tablets was studied in vitro. The formulation containing 10% carbomer showed a sustained-release profile comparable to that of a standard, commercially available, sustained-release preparation containing 400 mg lithium carbonate embedded in a composite material. In vivo the newly formulated and standard sustained-release lithium carbonate tablets were compared to an oral solution and conventional lithium carbonate tablets in 12 healthy subjects. These crossover studies showed that the sustained-release tablets produced a flatter serum concentration curve than the oral solution and conventional tablet, without loss of total bioavailability. 相似文献
32.
33.
Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. 总被引:1,自引:0,他引:1
Sylvie Rottey Guido Slegers Simon Van Belle Ingeborg Goethals Christophe Van de Wiele 《Journal of nuclear medicine》2006,47(11):1813-1818
This study was undertaken to evaluate changes in relative (99m)Tc-hydrazinonicotinamide (HYNIC)-annexin V tumor uptake over time in patients undergoing chemotherapeutic treatment at baseline and at 5-7 h and 40-44 h after treatment initiation. Imaging results are related to clinical outcomes, as assessed with response evaluation criteria in solid tumors (RECIST). METHODS: We prospectively included 20 patients (11 men and 9 women; mean age, 59.8 y; range, 22-75 y) scheduled for chemotherapy (n = 19) or bisphosphonate treatment (n = 1). Curable disease was present in 5 patients. The other patients had metastatic disease and were treated in a palliative setting. Three of the 20 enrolled patients were excluded from analysis: 1 patient ultimately refused the proposed chemotherapy treatment; because of difficulties with the labeling procedure, 1 patient did not receive a pretreatment scan; and 1 patient presented with an allergic reaction (rash and nausea) to the (99m)Tc-HYNIC-annexin V formulation. The remaining 17 patients underwent 3 scintigraphic scans with (99m)Tc-HYNIC-annexin V: before treatment and 5-7 h and 40-44 h after treatment initiation. The tumor response was evaluated with RECIST and related to observed changes in the ratios of tumor activity to background activity for the largest known lesion; values exceeding 25% the baseline value on either the 5- to 7-h scan or the 40- to 44-h scan were considered significant. RESULTS: With the proposed sequential imaging protocol and a 25% change threshold, responders to treatment could be separated from nonresponders with a 94% accuracy (16/17 patients). CONCLUSION: Sequential (99m)Tc-HYNIC-annexin V imaging may allow for assessment of the response to chemotherapy within 3 d after treatment initiation. 相似文献
34.
Hasan Yüksel Ali Riza Odaba?i Selda Demircan Aslihan Karul Leyla Didem Kozaci Kutsi K?seo?lu Kadir Kizilkaya Okay Ba?ak 《Gynecological endocrinology》2006,22(7):381-387
AIM: To evaluate the effects of oral continuous 17beta-estradiol plus norethisterone acetate (E2/NETA) replacement therapy on abdominal subcutaneous fat, serum leptin level (SLL) and body composition in postmenopausal women. MATERIALS AND METHODS: A 6-month, prospective, randomized, double-blind and placebo-controlled study was conducted. Forty-three healthy naturally postmenopausal women aged 43-65 years were randomly assigned to receive E2/NETA (2 mg E2 plus 1 mg NETA, n = 22) or placebo (n = 21). Fasting SLL by enzyme-linked immunosorbent assay, subcutaneous abdominal fat thickness (STh) by ultrasound and the anthropometric indices of body weight (BW), body mass index (BMI), waist and hip circumference (WC, HC) and waist-to-hip ratio (WHR) were recorded at the beginning and the end of the study. RESULTS: After 6 months of therapy, BW and SLL increased in the placebo group (p = 0.043 and 0.033, respectively). WC, HC and STh decreased significantly in the E2/NETA group (p = 0.002, 0.006 and 0.000, respectively) and they were also significantly lower in women receiving E2/NETA than in women taking placebo (p = 0.000, 0.034 and 0.000, respectively). At baseline, SLL and STh were positively correlated with all anthropometric indices except WHR. CONCLUSION: Oral continuous combined regimen of E2/NETA significantly reduced central fat accumulation as assessed by WC and STh, and attenuated the increase in SLL. The observed changes in SLL were highly and positively related to changes in STh. The oral continuous combined E2/NETA regimen appears to have protective effects on cardiovascular function and probably on metabolic diseases by its slimming effect upon WC in postmenopausal women. 相似文献
35.
复合珊瑚羟基磷灰石人工骨的研制及其成骨效应 总被引:12,自引:1,他引:11
目的 自行研制复合珊瑚羟基磷灰石人工骨并评估其成骨效应。方法 取南海澄黄滨珊瑚碳酸钙在特定条件下经过“热液交换反应”,制成单纯珊瑚羟基磷灰石(coralline Hydroxyapatite,CHA)人工骨,并将其与基因重组骨形态发生蛋白(rhBMP2)和几丁糖复合制成了三种复合珊瑚羟基磷灰石(composite Coralline Hydroxyapatite,CCHA)人工骨,将此三种不同配型的复合人工骨和单纯CHA人工骨分别植入四组24只SD大白鼠肌肉内。手术后2、4、6、8周取材进行组织学观察,计数高倍单位视野内的成骨细胞数量和炎性细胞数量。采用SPSS8.0统计软件处理系统分析。结果 术后各时期取材结果显示:B组(CHA rhBMP2)和D组(CHA rhBM2P 几丁糖)的单位视野内成骨细胞数量明显多于A组(单纯CHA)和C组(CHA 几丁糖):而C组和D组的单位视野内炎性细胞数量明显少于A组和B组。即D组人工骨的单位视野内的成骨细胞数量多、炎性细胞少。结论 rhBMP2-几丁糖/CHA复合人工骨不但具有显著的成骨诱导作用,还具有炎症反应轻及持续的诱导成骨作用,是一良好的骨移植替代物。 相似文献
36.
MUC-1基因在胃癌和外周血中的表达及临床意义 总被引:1,自引:0,他引:1
目的:检测胃癌MUC-1的表达情况及其与临床分期和转移的相关性。方法:应用逆转录聚合酶链反应(RT-PCR)和免疫组化方法检测胃癌活检标本和外周血中MUC-1基因和蛋白的表达水平。结果:在56例胃癌病例中MUC-1 mRNA阳性表达率为48.2%,MUC-1蛋白阳性表达率为53.6%,临床分期中I和II期病人阳性表达率MUC-1 RNA为33.3%,MUC-1蛋白为40%,而-Ⅲ期病人则分别高达65.4%和69.2%,二者差异有显著性意义(P<0.05),在淋巴结转移的患者中外周血的癌细胞MUC-1高表达,阳性率为73%,结论:MUC-1是一种较好反映胃癌恶性程度和转移性的肿瘤标志物。 相似文献
37.
Peter Kokol Marjan Mernik Jernej Završnik Kurt Kancler Ivan Malčić 《Journal of medical systems》1994,18(4):201-206
Computerized information systems, especially decision support systems, have become an increasingly important role in medical applications, particularly in those where important decision must be made effectively and reliably. But the possibility of using computers in medical decision making is limited by many difficulties, including the complexity of conventional computer languages, methodologies and tools. Thus a conceptual simple decision making model with the possibility of automating learning should be used. In this paper we introduce a cardiological knowledge-based system based on the decision tree approach supporting the mitral valve prolapse determination. Prolapse is defined as the displacement of a bodily part from its normal position. The term mitral valve prolaps (PMV), therefore, implies that the mitral leaflets are displaced relative to some structure, generally taken to be the mitral annulus. The implications of the PMV are the following: disturbed normal laminar blood flow, turbulence of the blood flow, injury of the chordae tendinae, the possibility of thrombus's composition, bacterial endocarditis, and finally hemodynamic changes defined as mitral insufficiency and mitral regurgitation. Uncertainty persists about how it should be diagnosed and about its clinical importance. It is our deep belief that the echocardiography enables properly trained experts armed with proper criteria to evaluate PMV almost 100%. But unfortunately, there are some problems concerned with the use of echocardiography. In that manner we have decided to start a research project aimed at finding new criteria and enabling the general practitioner to evaluate PMV using conventional methods and to select potential patients from the general population. To empower one to perform needed activities we have developed a computer tool called ROSE (computeRised prOlaps Syndrom dEtermination) based on algorithms of automatic learning. This tool supports the definition of new criteria and the selection of potential PMV-patients. 相似文献
38.
39.
40.